



Incorporating the Patient Voice into Clinical Trial Design and Conduct

Robyn Bent

Director, Patient Focused Drug Development
Center for Drug Evaluation and Research

Patient-focused drug development (PFDD) is a systematic approach to help ensure that **patients' experiences, perspectives, needs, and priorities are captured and meaningfully incorporated** into drug development and evaluation.



Better integrating the patient's perspective at critical points in drug development and decision making

Identify and **measure** outcomes and burdens that matter most to patients

- **Design** better clinical studies
- **Recruit** potential patients
- **Retain** study participants

Integrate patient-reported outcomes and patient preference information **into BR assessments**

Better Communicate information about drugs to patients and providers to **facilitate** informed decision-making



Patients can provide:



- Natural History Data
 - Input on relevance of research to patients
 - Help defining eligibility criteria
 - Input on meaningful endpoints
 - Education to the patient community
 - Input on protocol input and feasibility
- Increased awareness about trials
 - Participant feedback on trial experience
 - Input on informed consent content and processes
 - Members of Data and Safety Monitoring boards
 - Collaboration on post-marketing studies and surveillance initiatives

Resources are available on PFDD webpages

CDER Patient-Focused Drug Development Homepage

- Guidances
- COA Grant Program
- [FDA-led PFDD Meetings](#)
- Externally-led PFDD Meetings
- External Resources



- Browse upcoming meetings
- View past meeting materials
 - Slides, meeting recordings, transcript, agenda, summary report

Questions?

Email PatientFocused@fda.hhs.gov.

To get updates about CDER's Patient-Focused Drug Development programs, subscribe to our **free email subscription service** by clicking on the button near the top of the **homepage**.